Genomic Reassurance and Diagnostic Closure in Precision Oncology: A Preventable Hazard

Genomic findings can sharpen therapeutic decisions, but they can also provide false reassurance. In precision oncology, labels such as benign, nonactionable, or explanatory may be mistaken for evidence that symptoms or abnormal findings require no further evaluation. This Perspective argues that genotype–phenotype discordance should be treated as a safety signal. Simple report language, tumor‐board checks, and artificial intelligence guardrails can preserve the value of genomics without allowing a molecular explanation to become diagnostic closure.